Debbie Rigby rounds up the latest in research news
In this systematic review, the effectiveness of most therapies for fibromyalgia was not supported. Strong evidence supported only cognitive behavioural therapy for pain, as well as antidepressants and central nervous system depressants for pain and quality of life, but these associations were small. Common fibromyalgia symptoms include sleep disturbance, fatigue and morning stiffness.
JAMA Intern Med. Published online October 26, 2020.
In the Febuxostat versus Allopurinol Streamlined Trial (FAST) randomised controlled trial febuxostat was non-inferior to allopurinol therapy with respect to the primary cardiovascular endpoint of a composite of hospitalisation for non-fatal myocardial infarction or biomarker-positive acute coronary syndrome; non-fatal stroke; or cardiovascular death. Long-term use of febuxostat was not associated with an increased risk of death or serious adverse events compared with allopurinol.
Lancet, published 9 November 2020.
A randomised controlled trial of over 1000 patients compared 1.8g n-PUFA to placebo in older persons (70-82 years) with a recent (2-8 weeks) acute myocardial infarction. There was no reduction in clinical events (non-fatal AMI, unscheduled revascularization, stroke, all-cause death, heart failure hospitalization) after 2 years (21.4% vs 20.0%), and no difference in major bleeding events (10.7% vs 11.0%).
Circulation, first published 15 November 2020.
The STRENGTH Randomized Clinical Trial demonstrated that daily supplementation with 4g/day omega-3 fatty acids, compared with corn oil, resulted in no significant difference in a composite outcome of major adverse cardiovascular events (hazard ratio, 0.99). These findings do not support use of this omega-3 fatty acid formulation to reduce major adverse cardiovascular events in patients with high cardiovascular risk. participants were taking usual background therapies, including statins.
JAMA. Published online November 15, 2020.